Represents the total amount of non-contingent arrangement consideration.

No definition available.

Name:	irwd_CollaborativeArrangementAmountOfConsiderationTotalNonContingent
Namespace Prefix:	irwd_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Collaborative Arrangement, Expected Interest Income

+ References

No definition available.

+ Details

Name:	irwd_CollaborativeArrangementExpectedInterestIncome
Namespace Prefix:	irwd_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Collaborative Arrangement, Non-contingent Consideration Number of Installments

+ References

No definition available.

+ Details

Name:	irwd_CollaborativeArrangementNonContingentConsiderationNumberOfInstallments
Namespace Prefix:	irwd_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the percentage of net loss from commercialization.

+ References

No definition available.

+ Details

Name:	irwd_CollaborativeArrangementPercentageOfNetLoss
Namespace Prefix:	irwd_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Collaborative Arrangement, Regulatory and Administrative Services, Initial Term

+ References

No definition available.

+ Details

Name:	irwd_CollaborativeArrangementRegulatoryAndAdministrativeServicesInitialTerm
Namespace Prefix:	irwd_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Collaborative Arrangement, Threshold Royalty Percentage on Annual Net Sales

+ References

No definition available.

+ Details

Name:	irwd_CollaborativeArrangementThresholdRoyaltyPercentageOnAnnualNetSales
Namespace Prefix:	irwd_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the amount to be received by the company upon completion of milestone.

+ References

No definition available.

+ Details

Name:	irwd_MilestonePaymentToBeReceivedByCompanyUponMilestoneAchievement
Namespace Prefix:	irwd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the amount of pre-launch commercial services and supply chain services.

+ References

No definition available.

+ Details

Name:	irwd_PreLaunchCommercialServicesAndSupplyChainServices
Namespace Prefix:	irwd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Significant Financing Component, Transaction Price

+ References

No definition available.

+ Details

Name:	irwd_SignificantFinancingComponentTransactionPrice
Namespace Prefix:	irwd_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7(b))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

+ Details

Name:	us-gaap_InvestmentIncomeInterest
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	srt_ProductOrServiceAxis=irwd_CollaborativeArrangementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=irwd_ActivePharmaceuticalIngredientMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=irwd_AstraZenecaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementGeographicalAxis=irwd_ChinaHongKongAndMacauMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=irwd_CollaborativeArrangementCollaborationAndLicenseAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=irwd_CollaborativeArrangementCollaborationAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=irwd_CollaborativeArrangementTransitionServicesAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	irwd_AchievementOfMilestoneAxis=irwd_CommercializationMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=irwd_AstrazenecaServiceAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaboration, License, Co-Promotion and Other Commercial Agreements - China, Hong Kong and Macau (Details) $ in Thousands	1 Months Ended	3 Months Ended
	Sep. 30, 2019 USD ($) installment	Mar. 31, 2020 USD ($)	Mar. 31, 2019 USD ($)
Collaboration, License and Co-Promotion Agreements
Revenue		$ 79,943	$ 68,730
Collaborative arrangements revenue
Collaboration, License and Co-Promotion Agreements
Revenue		74,445	66,152
Sale of active pharmaceutical ingredient
Collaboration, License and Co-Promotion Agreements
Revenue		5,498	2,578
AstraZeneca \| Sale of active pharmaceutical ingredient
Collaboration, License and Co-Promotion Agreements
Revenue			3
AstraZeneca \| China, Hong Kong, and Macau \| Collaborative arrangements revenue
Collaboration, License and Co-Promotion Agreements
Collaborative arrangement, significant financing component, transaction price	$ 2,600
Collaborative arrangement, expected interest income		2,600
AstraZeneca \| China, Hong Kong, and Macau \| Collaborative arrangement, collaboration and license agreements
Collaboration, License and Co-Promotion Agreements
Revenue		332
AstraZeneca \| China, Hong Kong, and Macau \| Collaborative arrangement, collaboration agreements
Collaboration, License and Co-Promotion Agreements
Milestone payment to be received by company upon milestone achievement	90,000
Pre-launch commercial services and supply chain services			$ 200
Amount of non-contingent arrangement consideration	$ 35,000
Non-contingent consideration installments \| installment	3
Percentage of tiered royalties	20.00%
Revenue		32,400
Interest income		200
AstraZeneca \| China, Hong Kong, and Macau \| Collaborative arrangement, transition services agreement
Collaboration, License and Co-Promotion Agreements
Regulatory and administrative services initial term	2 years
AstraZeneca \| China, Hong Kong, and Macau \| Sale of active pharmaceutical ingredient
Collaboration, License and Co-Promotion Agreements
Revenue		$ 5,498
AstraZeneca \| China, Hong Kong, and Macau \| Commercialization milestone \| Collaborative arrangement, collaboration agreements
Collaboration, License and Co-Promotion Agreements
Percentage of net loss from commercialization (as a percent)		55.00%
AstraZeneca Service Agreement \| China, Hong Kong, and Macau \| Collaborative arrangement, collaboration agreements
Collaboration, License and Co-Promotion Agreements
Revenue		$ 200